At a glance
- Originator Eisai Co Ltd
- Class Piperazines
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 15 Dec 2003 No development reported - Preclinical for Stroke in Japan (unspecified route)
- 18 Sep 2001 Preclinical development for Stroke in Japan (Unknown route)